Health
WHO Calls for Global Solidarity to Stop Monkeypox
By Adedapo Adesanya
The rapidly spreading Monkeypox outbreak can be stopped, the World Health Organisation (WHO) said on Tuesday, “with the right strategies in the right groups”.
However, there is no time as “we all need to pull together to make that happen”, warned Dr Rosamund Lewis, WHO Technical Lead on Monkeypox, during a regular press briefing at the world health authority headquarters in Geneva, Switzerland.
This is coming after WHO’s Director-General, Mr Tedros Adhanom Ghebreyesus, declared the spread of the virus to be a public health emergency of international concern (PHEIC), the organization’s highest level of alert.
“Through this, we hope to enhance coordination, cooperation of countries and all stakeholders, as well as global solidarity,” Dr Lewis said.
WHO assessed the risk posed to public health by Monkeypox in the European region as high, but at the global level as moderate. With “other regions not at the moment as severely affected”, declaring a PHEIC was necessary “to ensure the outbreak was stopped as soon as possible”.
This year, there have been more than 16,000 confirmed cases of monkeypox in more than 75 countries but Dr Lewis said the real number was probably higher.
She pointed out that in the Democratic Republic of the Congo, several thousand cases were suspected, but testing facilities are limited.
“The global dashboard did not include suspected cases,” she said.
First identified in monkeys, the virus is transmitted chiefly through close contact with an infected person (you can read Business Post’s detailed explainer on the disease, here).
Until this year, the virus which causes Monkeypox has rarely spread outside Africa where it is endemic but reports of a handful of cases in Britain in early May signalled that the outbreak had moved into Europe.
Dr Lewis pointed out that stigma and discrimination must be avoided, as that would harm the response to the disease.
“At the moment the outbreak is still concentrated in groups of men who have sex with men in some countries, but that is not the case everywhere,” she said. “It is really important to appreciate also that stigma and discrimination can be very damaging and as dangerous as any virus itself,” she said.
Monkeypox could cause a range of signs and symptoms, including painful sores. Some people developed serious symptoms that need care in a health facility. Those at higher risk for severe disease or complications include pregnant women, children, and immunocompromised persons.
The WHO Lead said WHO was working with the Member States and the European Union on releasing vaccines, and with partners to determine a global coordination mechanism. She emphasized that mass vaccination was not required, but the WHO had recommended post-exposure vaccination.
Vaccine sharing should be done according to public health needs, country by country, and location by location as not all regions had the same epidemiology, she explained.
Dr Lewis stressed that countries with manufacturing capacity for smallpox and Monkeypox diagnostics, vaccines or therapeutics should increase production.
Countries and manufacturers should work with WHO to ensure they are made available based on public health needs, solidarity, and at a reasonable cost to countries where they were most needed.
The specialist explained that some 16.4 million vaccines were currently available in bulk but needed to be finished. The countries currently producing vaccines are Denmark, Japan, and the United States.
She reminded that the current recommendation for persons with Monkeypox was to isolate and not travel until they recovered; contact cases should be checking their temperature and monitoring possible other symptoms for the period of 9 to 21 days.
“When someone is vaccinated it takes several weeks for the immune response to be generated by the body”, she said.
According to Dr Lewis, the name “Monkeypox” is already present in the International Classification of Diseases, and a process had to be followed in order to potentially change its name.
By Adedapo Adesanya
The National Health Insurance Authority (NHIA) says the number of Nigerians enrolled in health insurance has risen to more than 22 million.
The Director-General of NHIA, Mr Kelechi Ohiri, said this resulted from the implementation of the mandatory health insurance, which has gained momentum nationwide.
He said this on Wednesday at the Annual General Meeting of the Nigerian Association of Insurance and Pension Editors (NAIPE) in Lagos.
Mr Ohiri said enrolment had increased to 22.03 million, representing a 35 per cent year-on-year growth, attributing this to stronger collaboration with state social health insurance agencies, ministries, departments and agencies, organised labour, employers, the private sector, and the gradual implementation of the mandatory health insurance provisions of the NHIA Act.
He said that the country had moved beyond policy formulation to delivering measurable improvements in healthcare access, service quality and consumer protection in line with the federal government’s health sector reform agenda.
According to him, Nigeria already has the necessary policies and legislation to achieve Universal Health Coverage, positing that the key challenge was effective implementation.
“The decisive variable is now implementation- consistent, rigorous and accountable execution that converts political commitment into healthcare access for real Nigerians,” he said.
Mr Ohiri said that the transition from the former National Health Insurance Scheme to the NHIA had strengthened regulation, consumer protection, accountability and strategic purchasing, while providing the legal and operational framework for achieving Universal Health Coverage.
He added that improving the experience of enrollees remained central to the Authority’s reform agenda.
According to him, NHIA has strengthened its complaints management system, introduced faster resolution timelines, and intensified compliance monitoring of Health Maintenance Organisations (HMOs) and healthcare providers.
He further added that NHIA had sanctioned facilities that failed to meet the required standards, adding that his organisation had resolved 3,878 complaints, representing an 87 per cent resolution rate, while 95 per cent of the cases were concluded within prescribed timelines.
Mr Ohiri noted that more than N14.2 million had been refunded to enrollees, while non-compliant healthcare facilities had been sanctioned.
He said NHIA had also introduced service standards, including a one-hour treatment commencement target for enrollees requiring urgent care, to improve access to timely and quality healthcare services.
The NHIA boss further disclosed that capitation payments to healthcare providers had been increased by 93 per cent.
He said fee-for-service reimbursements rose by 378 per cent to enable providers to invest more in personnel, equipment and infrastructure.
According to him, 7,592 healthcare facilities have been assessed under the SafeCare quality framework as part of efforts to institutionalise continuous quality improvement across the country.
Mr Ohiri also highlighted interventions targeted at vulnerable groups, including support for more than 48,500 pregnant women, expanded maternal and newborn healthcare services, the Vulnerable Group Fund, and improved access to healthcare for pensioners and retirees.
He said Universal Health Coverage could only be achieved if every Nigerian, regardless of income or location, had access to quality healthcare services.
By Modupe Gbadeyanka
The new one-hour authorisation response time ultimatum policy introduced by the National Health Insurance Authority (NHIA) has received the full backing of SUNU Health Nigeria Limited.
This policy was introduced by the agency to ensure enrollees get prompt approval codes to access care.
Healthcare service providers have been urged to report any Health Maintenance Organisation (HMO) that violates this initiative through an email, with the HMO in copy and a timestamp attached as evidence of the request. They may proceed to offer services to enrollees thereafter.
Speaking at the company’s second-quarter Providers’ Forum for the Lagos-Ogun region in Lagos recently, the chief executive of SUNU Health, Dr Moyosore Olomola, expressed optimism that this policy would improve healthcare delivery in the country, especially for enrollees, who crave quality service.
At the event themed Improving Quality and Access to Care Through Stronger Provider Network, and held at the Nigerian Institute of Medical Research (NIMR) in Yaba, Lagos, Mr Olomola reaffirmed the HMO’s commitment to operating within legal and operational frameworks to guarantee adequate care for enrollees.
“Access to care and quality of care remain key priorities in our healthcare systems. We know quite well that deliberate collaboration, strategic partnerships, and a shared commitment to excellence are required to achieve these priorities.
“A strong provider network is doubtless the backbone of any effective healthcare system. It ensures that our mutual enrollees receive the right care, at the right time, in the right place, and at the right price,” Mr Olomola, represented at the programme by the organisation’s Chief Operating Officer (COO), Dr Faith Nwachi, stated.
He further assured that SUNU Health would strictly adhere to the one-hour authorisation limit, stressing that this aligns seamlessly with one of the organisation’s core values—promptness and its corporate slogan, Humanity is the centre of our initiatives.
In a bid to further improve access and quality of care, SUNU Health also demonstrated its new operational software and Mobile app, aptly named SUNU Legacy.
Also speaking at the event, the NHIA Lagos State Coordinator (Ikeja), Dr Bethuel-Kasimu Abraham, noted that the forum’s expected outcome is to significantly reduce delays in accessing medical care.
Other key expectations include ensuring continuity of care, improving patient outcomes, and strengthening accountability among HMOs.
Addressing specific pain points faced by enrollees, the NHIA Ogun State Coordinator, Mr Dare Adefeso, acknowledged that the agency had received complaints regarding out-of-stock drugs and the discrimination of enrollees by certain providers.
He affirmed that the NHIA is actively addressing these issues, stressing that moving forward, every facility must ensure enrollees are properly catered to regardless of their status, provided they have an active health insurance plan.
Corroborating the long-standing legacy of SUNU Health, the Ogun State Director of the National Orientation Agency (NOA), Mrs Aishat Tiamiyu, shared that her agency is responsible for public information dissemination and has been enrolled with SUNU Health for over 25 years.
Commending the HMO’s stellar service over two decades, she called for the immediate enrollment of new NOA staff into the scheme.
The Providers’ Forum remains one of the strategic channels employed by SUNU Health to consistently engage healthcare providers, understand their operational challenges, introduce new software updates, and solidify partnerships aimed at fostering premium healthcare delivery across Nigeria.
By Aduragbemi Omiyale
The National Agency for Food and Drug Administration and Control (NAFDAC) has announced the recall of a sexual enhancement product known as WAP Sensual Enhancement Capsules.
In a statement on Monday, the Nigerian agency disclosed that the recall is due to “undeclared pharmaceutical ingredients” in the product, whose country of origin is unknown, but is marketed and distributed online in the US through eBay.
It was emphasised that the recall is being “voluntarily” made by the manufacturer, Best Supplements Best Prices Company.
The detection of the undeclared pharmaceutical ingredients was made by the US Food and Drug Administration (FDA).
Laboratory analysis by the US FDA revealed that the product contained undeclared sildenafil, tadalafil, and flibanserin, which were not mentioned on the product label. Such substances may include phosphodiesterase type-5 (PDE-5) inhibitors or related compounds commonly used for the treatment of erectile dysfunction, the statement by NAFDAC stated.
Sildenafil and tadalafil are ingredients in FDA-approved prescription drugs used to treat erectile dysfunction.
It was noted that these undeclared ingredients may interact with nitrates found in some prescription drugs, such as nitroglycerin, and may lower blood pressure to dangerous levels. Consumers with diabetes, high blood pressure, high cholesterol, or heart disease often take nitrates.
Flibanserin is the active ingredient in an FDA-approved prescription drug used to treat low sexual desire in women. Flibanserin can cause drowsiness, sedation, dangerously low blood pressure, and fainting, especially when combined with alcohol.
Consumers have been encouraged to report compromised products (medicines or medical devices) to the nearest NAFDAC office, call 0800-162-3322, or send an email to sf******@********ov.ng.
